According to a Bloomberg story, nearly 16,800 adverse events associated with metal-on-metal hip implants were reported in the United States from 2000 through 2011.
Metal-on-metal hip implants, which have both a ball and socket coated in an alloy made of cobalt and chromium, were originally introduced as an ostensibly more durable alternative to earlier plastic and ceramic models. But a number ...
continue reading...
According to a Reuters story, sales representatives for Abbott Laboratories Inc’s subsidiaries routinely buy gifts for physicians in India to bribe them into prescribing certain drugs.
The practice is so blatant that an Abbott sales-strategy guide explicitly states that doctors who pledge to prescribe the company’s branded drugs, or who’ve already prescribed certain amounts, can expect gifts such as coffee makers, cookware and vacuum cleaners in return.
According to the story, public ...
continue reading...The U.S. Food and Drug Administration intends to give priority review to Johnson & Johnson’s experimental treatment for multidrug-resistant tuberculosis.
According to a story in the Newark Star Ledger, Johnson & Johnson’s Janssen Research & Development unit applied for approval to market bedaquiline, or TMC207, on June 29. The drug would be included in combination therapy for adults with multidrug-resistant tuberculosis lung infections.
Under the FDA’s standard review process, the agency aims ...
continue reading...
According to Bloomberg, a Louisiana appeals court declined to throw out an award of nearly $258 million that Johnson & Johnson must pay to state officials, over illegal marketing of its antipsychotic drug Risperdal.
Jurors in Louisiana found Johnson & Johnson officials violated the state’s Medicaid fraud laws 35,542 times over Risperdal. Lawyers for the state argued that the company defrauded Louisiana’s Medicaid program by wrongfully marketing the drug to doctors ...
continue reading...According to a story in the Boston Globe, Johnson & Johnson has appointed Bayer executive Sandra E. Peterson to oversee the company’s troubled consumer health and manufacturing operations.
The move is an attempt by Alex Gorsky, who became CEO of Johnson & Johnson in April, to address a host of quality, legal and ethical problems involving products and sales practices.
Those problems include what the article characterizes as “an eye-popping series of ...
continue reading...
On the first day of trial, Johnson & Johnson settled a lawsuit centering on complaints that its antipsychotic drug Risperdal caused a male plaintiff to grow breasts, Bloomberg reports. The terms of the settlement are confidential.
It was the first of about 130 lawsuits alleging that Risperdal caused young males to grow breasts. An additional 290 allege other personal injuries caused by the drug.
A lawyer for the plaintiff claimed he suffered ...
continue reading...
